In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
The numbers of IBD patients using medicinal marijuana is increasing at a rapid pace and many patients who use it feel that it improves their quality of life. We need research-based evidence to determine the underlying connection. Does it improve symptoms that make patients feel better (pain, loss of appetite, decreased stress and increased sleep), or does it actually have an anti-inflammatory effect on the gut?
For those patients who have failed anti-TNF alpha therapy, what is the next best step? Is Entyvio, Stelara, or Xeljanz more effective?
Many patients, myself included, have either not responded to anti-TNF therapies or have lost response. It would be helpful for both doctors and patients to know what the next best step is.
Create a database that tracks the long-term outcomes for patients on biologic medications (Remicade, Humira, Cimzia, Simponi, Tysabri, and Entyvio) to assess their long-term efficacy.
As IBD research and treatments progress, biologics are becoming an ever-more staple part of a patients treatment regimen. However, many patients still fail to respond effectively to these medications while others can maintain long-term remission specifically because of them. I believe it is important for the IBD community to further explore why this variation in response occurs, and tracking those that respond effectively to these biologic drugs can, perhaps, help us to better understand why some respond while others do not.
Anyone with a disease can tell you that high stress environments make symptoms worse and relaxation techniques often help. It has also been shown, primarily in animal studies, that "stress hormones" like cortisol or changes at in epigenes have severe repercussions across the body. Can managing these help control symptoms or remission?
“Milk fats increase the amount of taurine conjugated bile acids that promote growth and metabolic activ ity of sulphate reducing, bile acid tolerant bacterial species, which in turn stimulate pathogenic immune responses in genetically susceptible hosts” Sartor, R. B. Nat. Rev. Gastroenterol. Hepatol. 9, (2012)
Sequence the DNA of components of patients' microbiomes to find any associations with variables like severity of symptoms, location of disease, extra-intestinal manifestations and response to medications.
The 'genome' of a patient's microbiome could provide guidance in treating with specific medications and/or probiotics.
Is the use of probiotics significantly beneficial for IBD patients? If so, what types are most beneficial for mucosal healing and prevention of future disease activity?
Current treatments for IBD focus heavily on the body's immune response and "warding off" the disease. It is important to do what we can to heal the intestine after damage has occurred and prevent damage to the best of our ability.
Do longitudinal evaluation of Vit D3 findings relate with disease activity, progress, treatment response, or remission?
Crohn's patients appear to have consistently low Vit D3, and disease prevalence is higher in northern latitudes with less sun and lower natural Vit D3 exposure and levels. Ultimately conduct longitudinal study to evaluate benefit aggressive management of Vit D3 to assist as adjunct in therapy, and to consider benefit of supplementation in at possible risk populations (1st degree family at high latitudes).
I am interested to know whether inflammation in the colon contributes to anxiety symptoms, especially during peristalsis
For many UCers, stress is a big factor of their UC (I have periods where I feel anxious for no apparent reason). I am wondering if the link could be inflammation in the colon triggering the anxious response
Patient-Reported Outcomes and Quality of Life in Patients with Ileal Pouch-Anal Anastomosis (IPAA)
Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease